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Abstract 
Background: After myocardial infarction, necrotic cardiomyocytes release damage-associated proteins that 
stimulate innate immune pathways and macrophage tissue infiltration, which drives inflammation and 
myocardial remodeling. Circulating inflammatory extracellular vesicles play a crucial role in the acute and 
chronic phases of ischemia, in terms of inflammatory progression. In this study, we hypothesize that the 
paracrine effect mediated by these vesicles induces direct cytotoxicity in cardiomyocytes. Thus, we examined 
whether reducing the generation of inflammatory vesicles within the first few hours after the ischemic event 
ameliorates cardiac outcome at short and long time points.  
Methods: Myocardial infarction was induced in rats that were previously injected intraperitoneally with a 
chemical inhibitor of extracellular-vesicle biogenesis. Heart global function was assessed by echocardiography 
performed at 7, 14 and 28 days after MI. Cardiac outcome was also evaluated by hemodynamic analysis at 
sacrifice. Cytotoxic effects of circulating EV were evaluated ex-vivo in a Langendorff, system by measuring the 
level of cardiac troponin I (cTnI) in the perfusate. Mechanisms undergoing cytotoxic effects of EV derived from 
pro-inflammatory macrophages (M1) were studied in-vitro in primary rat neonatal cardiomyocytes. 
Results: Inflammatory response following myocardial infarction dramatically increased the number of 
circulating extracellular vesicles carrying alarmins such as IL-1α, IL-1β and Rantes. Reducing the boost in 
inflammatory vesicles during the acute phase of ischemia resulted in preserved left ventricular ejection fraction 
in vivo. Hemodynamic analysis confirmed functional recovery by displaying higher velocity of left ventricular 
relaxation and improved contractility. When added to the perfusate of isolated hearts, post-infarction 
circulating vesicles induced significantly more cell death in adult cardiomyocytes, as assessed by cTnI release, 
comparing to circulating vesicles isolated from healthy (non-infarcted) rats. In vitro inflammatory extracellular 
vesicles induce cell death by driving nuclear translocation of NF-κB into nuclei of cardiomyocytes.  
Conclusion: Our data suggest that targeting circulating extracellular vesicles during the acute phase of 
myocardial infarction may offer an effective therapeutic approach to preserve function of ischemic heart. 
Key words: myocardial infarction, inflammatory extracellular vesicles, macrophages, TLR4 axis 
Introduction 
Ischemic injury during the acute phase of 
myocardial infarction (MI) leads to initiation of a 
prompt inflammatory response. Cellular debris and 
metabolic products such as ATP, ions and adenosine, 
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act as damage-associated molecular patterns 
(DAMPs), inducing the so-called “sterile inflamma-
tion” as it is not associated with pathogen [1, 2]. 
DAMPs bind specific pattern recognition receptors 
(PRRs) on the surface of surviving cells surrounding 
the necrotic lesion, including adult cardiomyocytes 
(CM), thus activating macromolecules to aggregate 
and form inflammasome [1, 3]. Nucleotide-binding 
oligomerization domain-like receptors (NLRs) are 
tripartite large proteins involved in formation of the 
inflammasome, recruitment of pro-caspase-1, and 
promotion of autocatalytic activation of the 
pro-inflammatory cytokines IL-1β, IL-18 as well as the 
release of IL-1α, HMGB1 and other chemokines [1, 4]. 
Released cytokines recruit leukocytes (neutrophils, 
monocytes/ macrophages) from the bone marrow 
and spleen to the site of injury [5, 6]. Infiltrating 
macrophages (MΦ), once homed into the necrotic 
area, undergo biphasic activation: MΦ exhibit a 
pro-inflammatory M1 phenotype early and become 
polarized toward an anti-inflammatory M2 
phenotype later post- MI [7]. The systemic release of 
different subsets of cytokines and proteins by 
polarized M1/M2 macrophages implies the activation 
of toll-like receptor (TRLs) and subsequent NF-κB 
signalling cascades [8]. This paracrine secretion may 
be responsible for accelerated myocardial cell death 
during the acute phase of MI [9, 10]. 
In addition to the conventional ER-Golgi 
secretory pathway, proteins and alarmins are 
segregated in membrane-enclosed compartments and 
secreted in nanosized extracellular vesicles (EV) [11, 
12]. Importantly, inflammosome activity correlates 
with enhanced secretion of EV and modulation of 
their cargo [11, 13]. Furthermore, both the amount and 
content of plasma-derived EV correlate with severity 
of cardiac injury [14]. In patients the acute phase of 
MI, transiently increases concentrations of platelet-, 
endothelial cell-, and leucocyte-derived micro-
particles and EV [15-17]. In this context it is important 
being aware that EV cargo (proteins, mRNA, 
microRNA etc.) not only represents a measurable 
indicator of biological state or condition, it serves to 
deliver bioactive molecules from cells of origin to 
recipient cells and contribute to processes, such as 
atherosclerosis, thrombosis, and inflammation [18-20]. 
EV smallest fraction, are at least in part responsible for 
cardiac dysfunction in a model of LPS-induced sepsis 
[21]. In this model, LPS treatment enhances the release 
of exosomes by macrophages that act as autocrine and 
paracrine signal mediators and contribute to impair 
cardiac function [21]. While it is well accepted that 
circulating EV are implicated in exacerbating 
inflammatory responses after MI, their direct effects 
on CM remain largely uncharacterized.  
We hypothesized that circulating inflammatory 
EV might have direct cytotoxic effects on CM. We 
used an ex vivo Langendorff system to directly assess 
whether post-MI plasma-derived EV induce cell death 
in CM, avoiding interference by other systemic effects. 
In vivo, we sought to evaluate whether the blockade of 
EV release concomitant with the acute ischemic event 
reduces myocardial injury, attenuates adverse cardiac 
remodeling and ameliorates heart function in both the 
short- and long- term after MI. Finally we explored 
the in vitro mechanisms underlying the effect of M1- 
and M2-derived EV on CM. 
Results 
Post-infarction circulating extracellular 
vesicles exert direct cytotoxic effects on 
cardiomyocytes 
EV were isolated from blood samples of rats 
before and 24 hrs after coronary ligation. EV were 
isolated using serial centrifugation procedure 
followed by washing step through the resuspension of 
the pellet and repeating the centrifugation steps as 
depicted in Figure 1A (see methods). This protocol 
allows us to purify plasma-derived EV that were 
enriched in exosomal fraction as indicated by the 
expression of typical markers of endosomal-derived 
vesicles such as TSG101, CD63 (Figure S1A) and 
confirmed by transmission electron microscopy 
analysis (TEM) (Figure S1B).The absence of 
contaminants was verified by immunoblot for plasma 
specific proteins such as apolipoprotein A1 and 
albumin (Figure S1A) [22]. Moreover, a large 
subpopulation of particles showed a size consistent 
with exosomes (50-150 nm) as assessed by 
Nanoparticle Tracking Analysis (NTA) (Figure S1C). 
However, because EV preparations were not 
homogeneous, we used the term EV, which is 
inclusive, but not restricted to exosomes throughout 
the manuscript.  
Although size distribution of isolated EV did not 
differ pre- and post-MI, the number of circulating EV 
was significantly increased 24 hrs after MI (EV 
post-MI) compared to before MI (EV pre-MI) as 
assessed by NTA (Figure 1B). This trend was also 
appreciable by WB for the expression of EV markers 
TSG101, CD63 and CD81 (Figure 1C).  
To test whether plasma-derived circulating EV 
may behave differently on CM when isolated before 
or after MI, primary neonatal rat myocytes (NRVM) 
were exposed to 107particles/cm2 for 12 hrs in a serum 
free condition. EV post-MI, but not pre-MI, induced 
cell death in NRVM (Figure 1D). 
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Figure 1. Plasma-EV analysis. (A) Plasma derived EV purification protocol. (B) Dynamic light scatter analyses of particle size and concentration of plasma derived EV before 
(pre-MI) and after (post-MI) myocardial infarction (n=5 repeated measurements of 5 different plasma samples per group), red lines represent standard deviations. (C) Western 
blot analysis of specific exosomal markers TSG101, CD63 and CD81. (D) Quantification of plasma derived EV cytotoxicity on rat primary neonatal cardiomyocytes. n=4 
independent experiments treated with 4 different pools of EV. Left panels are representative images of viability assay for the conditions without EV (w/o EV), EV derived from 
plasma before (EV pre-MI) and after (EV post-MI) myocardial infarction.Viable cells stain green, dead cells red. All data are presented as mean ± SEM and analyzed by one-way 
analyses of variance-ANOVA with post-hoc multiple comparisons using the Bonferroni correction (**p < 0.01). Mean, SEM and statistics are reported in full in Table S1. 
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GW4869 reduces the number of circulating 
extracellular vesicles and modifies their 
pro-inflammatory cytokine cargo 
We sought to determine if the blockade of EV 
release during the acute phase of MI would diminish 
adverse cardiac remodelling and ameliorate heart 
function. We used GW4869 as chemical inhibitor as it 
has been shown to block the secretion of EV in vitro 
[23, 24] and in vivo after IP injection [21, 25, 26]. One 
hour before coronary ligation, rats were injected IP 
with either GW4869 (5mg/kg) or saline solution 
added of DMSO which was used to dissolve the 
compound (Vehicle). NTA analysis (Figure 2A) 
showed that MI significantly increased the total 
number of circulating EV in rat plasma at 24 hrs 
compared to baseline (pre-MI). The increased number 
of circulating EV post-MI, was not affected by the 
presence of DMSO in vehicle solution as the 
concentration of EV per ml was comparable with that 
of animals undergoing MI but not subjected to IP 
injection (Figure 2A). The boost of EV was reduced by 
approximately 50-60% in animals pre-treated with 
GW4869 (Figure 2A). Interestingly the number of total 
circulating EV drops down at basal level at 48hrs 
post-MI in both, control and treated animals. Thus, a 
single injection of GW4869, before the induction of 
MI, only affect the release of EV in time window of 
approximately 24 hrs (Figure S2A).  
GW4869 inhibits neutral SMase (nSMases) and 
reduces the secretion of EV by blocking the ceramide- 
dependent budding of intraluminal vesicles (ILV) into 
the lumen of multivesicular bodies (MVB) [27]. Since 
it is well known that ceramide is a bioactive 
sphingolipid involved in many biological functions 
such as proliferation, apoptosis, differentiation and 
inflammation,[28] we assessed by LC-MS/MS 
whether the ceramide composition of circulating EV 
was impaired by the GW4869 treatment. The large 
majority of ceramide isoforms measured in EV 
samples isolated from 300 µl of plasma, was increased 
after MI as compared to baseline. The treatment with 
GW4869 does not affect ceramide isoforms 
composition as compared to vehicle injected animals 
(Figure 2B). We also assessed the composition of EV 
content in terms of inflammatory markers and 
cytokines. 24 hrs after MI, plasma-derived EV were 
enriched with pro-inflammatory cytokines IL1α, IL1β 
and Rantes. EV of animals receiving GW4869 enclosed 
M2-associated cytokines such as IL4, IL6 and IL10 
(Figure 2C). As shown in a previuos papers, EV not 
only transfer their protein to the target cells, they are 
also able to transfer mRNA [29, 30]. Thus, we verified 
whether the cargo of pro-inflammatory cytokines that 
was observed following MI, was also accompanied by 
the presence of specific mRNA encoding for those 
cytokines. As showed in supplementary figure 2B, EV 
cargo does not contain mRNA for iNOS, INFγ, IL1α. 
The presence of vesicle mRNA was detected for IL1β, 
Rantes, IL6. However, the level of expression did not 
change between groups (Figure S2B). EV post-MI 
Vehicle expressed higher levels of inflammatory 
markers iNOS and CD68, as compared to EV pre-MI 
and EV post-MI GW4869 (Figure 2D). Moreover, in 
GW4869 pre-treated animals resulted in a diminished 
cell infiltration (CD68+ cells) in the heart tissue as well 
as reduced TNF-α (Figure 2E-F), thereby confirming 
that circulating EV may exacerbate inflammatory 
responses during the acute phase of MI.  
Inhibition of extracellular vesicles release 
mitigate myocardial dysfunction in rat model 
of myocardial infarction 
To monitor the functional effects of GW4869, rats 
underwent echocardiography at 1 day (baseline), 7 
and 28 days after MI (Figure 3A). Left ventricular 
ejection fraction (LVEF) was significantly decreased at 
24 hrs after MI in both groups. At 7 days, there was a 
trend in preservation of LVEF in GW4869 injected 
animals as compared to vehicle which became 
statistically significant at 28 days (Figure 3B). Parallel 
changes in left ventricle (LV) end-systolic and LV 
end-diastolic volumes were observed (Figure 3C-D). 
To confirm echo analysis a subset of animals were 
subjected to hemodynamic measurements by Millar 
catheter. From LV pressure/volume loops (Figure 
3E), the time constant of isovolumic LV pressure (Tau) 
was significantly increased in vehicle injected rats and 
rescued to control levels in GW4869 injected rats, 
indicating improved diastolic relaxation (Figure 3F). 
Moreover, GW4869 significantly increased LV systolic 
pressure (Figure 3G) and improved dP/dt max and –
dP/dt min (Figure 3H). Histological analysis dis-
played smaller scar in GW4869 group as compared to 
vehicle (Figure 3I). Pre-treatment of rats with GW4869 
significantly improved animal survival after MI 
compared to vehicle pre-treated animals (Figure 3J). 
We performed additional set of experiments to 
test whether the inhibition of EV release was also 
protective in the context of ischemia-reperfusion (I/R) 
which is generally accepted as more translational 
model compared to permanent coronary artery 
ligation (LAD) (Figure 4A). LVEF was significantly 
decreased at day 1 after I/R in both groups. At 7 days 
LVEF was significant higher in GW4869 injected 
animals as compared to vehicle and it was preserved 
at 28 days (Figure 4B). Parallel changes in LV 
end-systolic volumes were observed, whereas there 
was no difference in LV end-diastolic volumes (Figure 
4C-D). Although the LV Tau constant was not 
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significantly different between vehicle and GW4869 
(Figure 4E) the latter showed significantly increased 
LV systolic pressure (Figure 4F). In animals 
pre-treated with GW4869, scar size, as assessed by 
Masson’s trichrome staining, was significantly 
reduced as was mortality rate (Figure 4G-H). 
 
 
Figure 2. Inhibition of extracellular vesicles release regulates inflammation in heart and reduces circulating inflammatory extracellular vesicles after MI. 
(A) NTA analysis, cumulative curves for concentration and size distribution of plasma-derived EV. EV pre-MI (grey; n=5 repeated measurements of 14 different plasma samples), 
EV post MI GW4869 (blue; n=5 repeated measurements of 7 different plasma samples), EV post MI vehicle (yellow; n=5 repeated measurements of 7 different plasma samples) 
and EV post MI from not injected animals (reference line bordeaux). (B) LC-MS/MS quantification of EV ceramide content for EV pre-MI (gray reference line), EV post-MI vehicle 
(yallow bars) and EV post-MI GW4869 (blue bars), n=6 different plasma samples. All data are presented as mean ± SEM pmol/300ml plasma samples and normalized over pre-MI 
ceramide levels (fold increase vs EV pre-MI). (C) EV cytokine content analyses. Data are presented as mean fold change (over blank) ± SEM of 4 independent experiments. (D) 
Western blotting analysis and relative quantification of specific exosomal markers TSG101, CD63 and CD81 and specific inflammatory macrophages markers iNOS and CD68. 
(E) Representative images and quantification of infiltrated CD68+ (stained in red) macrophages in heart section 24 hrs post-MI (Sham: n=7, GW4869: n=8, vehicle: n=7 heart 
section/group). (F) Quantification of TNFa in heart tissue 24hrs post-MI (Sham: n=9, GW4869: n=6, vehicle: n=7 heart section/group). All data are presented as mean ± SEM and 
analyzed by one-way ANOVAs with post-hoc multiple comparisons using the Bonferroni correction (*p < 0.05, **p < 0.01). Mean, SEM and statistics are reported in full in Table 
S2. 
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Figure 3. In vivo inhibition of extracellular vesicle release mitigates myocardial dysfunction after permanent coronary artery ligation. (A) Scheme depicting 
the study protocol. LAD occlusion was induced in rats one hour after IP injection of GW4869 or vehicle. (B-D) Echocardiography evaluation of LVEF, LVSV and LVDV (n= 6 
rats/group). Data ara analyzed using two-way ANOVAs followed by Bonferroni post-hoc test. Data are presented as mean ± SEM (*p < 0.05, **p < 0.01) (E) Representative LV 
pressure-volume cardiac loops. (F-H) Hemodynamic analyses of LV systolic pressure, LV relaxation velocity (tau index) and LV contractility capacity (dP/dt) (n=4 sham, n=5 
vehicle, n=6 GW4869 treated animals). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01 (one-way ANOVA with post-hoc multiple comparisons using Bonferroni 
multiple comparisons correction). (I) Masson’s trichrome staining for quantification of infarct size (n = 8 animals per group). The percentage of scar size was calculated by 
normalizing blue fibrotic area by total section area. Variables are presented as mean ± SEM and analyzed by Student’s T test **p < 0.01. (J) Kaplan-Meier survival curve. (GW4869 
survival= 96.15% n=26 animals, Vehicle survival = 78.12% n= 32 animals; HR 4.44; 95%-CI 1.01-19.65; p = 0.04). Mean, SEM and statistics are reported in full in Table S3. 
 
Ex vivo assessment of effects of extracellular 
vesicles on cardiomyocyte cytotoxicity 
To assess whether the impairment of heart 
function was due to direct cytotoxic effects of 
circulating EV on adult CM and to avoid interference 
of circulating cells as source of soluble factors and 
vesicles, an acellular physiologic solution containing 
plasma-derived EV was used to perfuse normal hearts 
in a retrograde (Langendorff) ex vivo system. Equal 
amounts (5 x 1010) of circulating EV pre-MI and 
post-MI from vehicle (EV post-MI Vehicle) or GW4869 
(EV post-MI GW4869) injected animals, were added to 
the perfusate and circulated for 2 hrs (Figure 5A). 
Saline without EV was used as control solution. Heart 
function was evaluated by end diastolic pressure 
(EDP) and CM death was assessed by measuring the 
release of cTnI and LDH into perfusate. EV-Vehicle 
was detrimental on heart function as early as 40 
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minutes. Both EDP and cTnI level increased over time 
with the physiological worsening of heart function 
occurring in the presence of control solution (Figure 
5B-C). Although at later time point respect to the 
increasing level of cTnI, the release of LDH was also 
augmented in hearts perfused with EV post-MI 
Vehicle (Figure 5D). Moreover, tissue immuno-
fluorescence of ex vivo perfused heart revealed a 
striking expression of cleaved caspase 3 and 7 in EV 
post-MI Vehicle group as compared to pre-MI and EV 
post-MI GW4869 (Figure 5E-F). Data on activation of 
caspases were also confirmed in vitro in NRVM 
(Figure S3). All together these data showed that 
independently from necrotic massive event 
subsequent to acute ischemia, circulating EV act 
directly on viable CM, inducing cell death via 
mechanisms retrieving apoptosis and pyroptosis. 
 
 
Figure 4. In vivo inhibition of extracellular vesicle release mitigates myocardial dysfunction after ischemia-reperfusion injury. (A) Scheme depicting the study 
protocol. I/R model was induced by ligating the left descending anterior coronary that was than released after 30 min. Rats underwent IP injection of GW4869 or vehicle one hour 
before coronary reperfusion. (B-D) Echocardiographic evaluation of LVEF, LVSV and LVDV (n=6 rats/group). Data were analyzed using two-way ANOVAs followed by 
Bonferroni post-hoc tests. Data are presented as mean ± SEM (*p < 0.05, **p < 0.01). (E-F) Hemodynamic analysis of LV relaxation velocity (tau index) and LV systolic pressure 
(n=3 sham, n=5 vehicle, n=5 GW4869 treated animals). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01 (one-way ANOVAs with post-hoc Bonferroni multiple 
comparisons correction). (G) Masson’s trichrome staining for quantification of infarct size (n =8 GW4869 rats, n=6 vehicle animals). The percentage of scar size was calculated 
by normalizing blue fibrotic area with total section area. Variables are presented as mean ± SEM and analyzed by Student’s T test **p < 0.01. (H) Kaplan-Meier survival curve 
(GW4869 survival= 100% n=10 animals, Vehicle survival = 58.33 % n= 12 animals; HR 9.63; 95%-CI 1.36-68.12; p = 0.023). Mean, SEM and statistics are reported in full in Table 
S4. 
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Figure 5. Ex-vivo effects of plasma-derived extracellular vesicles cytotoxicity on cardiomyocytes. (A) Experimental design. Normal rat hearts were retrogradely 
perfused for 90 min. PBS, EV pre-MI, EV post-MI GW4869 or EV post-MI Vehicle were added to the perfusion solution. (B) Evaluation of end-diastolic pressure (w/o EV: n=5; 
EV pre-MI: n=5; EV post-MI GW4869: n=6; EV post-MI Vehicle: n=6). (C) Cardiac troponin I levels in Langendorff perfusate (w/o EV: n=5; EV pre-MI: n=5; EV post-MI GW4869: 
n=6; EV Post-MI Vehicle: n=6). (D) LDH levels in Langendorff perfusate (w/o EV: n=5; EV pre-MI: n=5; EV post-MI GW4869: n=6; EV post-MI Vehicle: n=6) (E-F). Representative 
images of immunofluoresce for the cleaved caspase 3 and cleaved caspase 7 in heart tissue after 2 hrs of perfusion with plasma derived EV (w/o EV: n=6; EV pre-MI: n=6; EV 
post-MI GW4869: n=6; EV post-MI Vehicle: n=6). Cleaved caspeses stain green, cardiomyocytes stain red. Data are analyzed using two-way ANOVAs followed by Bonferroni 
post-hoc test and are presented as mean ± SEM. **p<0.01 EV post-MI Vehicle vs. either EV post-MI GW4869, EV pre-MI, and w/o EV. Mean, SEM and statistics are reported in 
full in Table S5. 
 
Plasma-derived extracellular vesicles from a 
rat model of ischemia induce cytotoxic effects 
in cardiomyocytes through activation of the 
TLR4/NF-κB axis 
A recent paper by Dalvi et.al showed that EV 
derived from immune-activated monocytes stimulate 
TLR4/MyD88 pathway thereby activating NF-κB [31]. 
Cardiomyocytes express the TLR4 receptor [32] and 
its expression and activation in infarcted and remote 
areas following MI contributes to LV remodelling and 
functional impairment [33]. Inhibition of TLR4 has 
been described as anti-apoptotic in an animal model 
of ischemia/reperfusion [34]. Therefore we checked in 
vitro whether pro-inflammatory circulating EV act on 
NRVM through this axis. 1x107 EV/cm2 derived from 
plasma of pre-MI rats and vehicle or GW4869 treated 
and infarcted animals were added to the medium of 
NRVM. As expected, EV-Vehicle induced 
significantly higher cell death in NRVM as compared 
to EV-GW4869. The latter was not different from 
Theranostics 2020, Vol. 10, Issue 6 
 
 
http://www.thno.org 
2781 
control treatments (EV pre-MI and medium w/o EV). 
The cytotoxic effect of EV-Vehicle was abolished 
when NRVM were pre-treated with the TLR4 specific 
inhibitor TAK242 (Figure 6A). We also verified 
whether the stimulation of TLR4 receptor induced the 
transloncation of NF-κB into nuclei of NRVM. Both 
immunofluorescence assay (Figure 6B) and Western 
Blots on cytosolic and nuclear fractions (Figure 6C), 
confirmed this hypothesis. The activation and 
translocation of NF-κB was inhibited by TAK242. 
Nuclear translocation of NF-κB was also assesed ex 
vivo, in adult CM isolated from healty heart perfused 
with EV-Vehicle for 2 hours (Figure S4). These data 
confirmed that the TLR4/NFκB axis plays an 
important role in mediating EV-induced cell death on 
CM. 
Extracellular vesicles from pro-inflammatory 
bone marrow-derived macrophages are 
cytotoxic in vitro  
To assess the hypothesis that circulating 
pro-inflammatory EV mostly derive from activated 
macrophages, rat bone marrow-derived primary 
monocytes were isolated and cultured in vitro. 
Monocytes were first differentiated into macrophages 
(MΦ) and subsequently polarized to M1 or M2, by 
supplementing the culture medium with specific 
cytokines (Figure 7A, see methods). Macrophages 
were characterized for mRNA expression of specific 
transcripts. M1 express typical pro-inflammatory 
markers such as iNOS, TNFα and TLR4 whereas, M2 
express Arginase1 and CD206 (Figure 7B). M1 and M2 
polarization was also confirmed by WB for the 
expression of iNOS, TLR4 and increased expression of 
CD68 as compared to MΦ and M2 (Figure 7C). EV 
derived from conditioned medium of cultured cells 
were profiled for NTA analysis (Figure 7D) and 
characterized for the expression of exosomes markers 
such as TSG101, CD63 and Alix (Figure 7E; Figure 
S1B). NTA profiles showed typical size distribution of 
exosomes or small EV (Figure 7D). Isolated EV were 
used in a functional assay with NRVM. EV released 
by M1, but not those released from M2, induced cell 
death in normoxic NRVM (Figure 8A). To evaluate 
the effects of macrophages-derived EV on CM 
subjected to ischemia, we performed functional assay 
in condition of FBS starvation at 1% of O2. As 
aspected, the rate of cells death was augmented in all 
conditions as compared to normoxia ( Figure 8A, 
Figure S5). In presence of M1-derived EV, CM 
mortality reached 80% (Figure S5) which is double as 
compared to normoxia (Figure 8A). Moreover, EV 
derived from medium conditioned by M1 activated 
nuclear translocation of NF-κB via TLR4 (Figure 
8B-C). Specific inhibition by TAK242 of TLR4 receptor 
activity abrogated NF-κB translocation and reduced 
cytotoxic effects. Finally to asses whether protein 
present onto surface of EV are important for the 
signaling cascade leading to cytotoxic effect, we 
performed acid-washing procedure (see method) 
aiming to remove surface antigens by incubating 
vesicles for 5 min with acid glycine [35]. The efficency 
of protocol was monitored by dot-plots immunoassay 
against CD63 known to be abundantly expressed on 
the surface of EV (Figure S6A). Acid-washed EV 
Vehicle and EV M1 had reduced toxicity as compared 
to untreated counterpart EV (Figure S6B-C). These 
findings suggest that EV surface proteins contribute 
to EV-mediated cell toxicity on CM.  
Discussion 
Numerous preclinical studies have approached 
ischemic heart disease by targeting different players 
and cofactors involved in inflammation, occurring 
during the acute event of MI, to reduce organ 
remodelling and dysfunction in the heart [36-39]. A 
recombinant human IL-1 receptor antagonist has been 
tested in a model of ischemia in mice by using 
immediate or delayed administration (24 hours after 
ischemia). IL-1 blockade was associated with a 
significant reduction in cardiomyocyte apoptosis and 
attenuation of adverse cardiac remodelling in both 
immediate- and delayed- treatment groups [36]. Of 
note: treatment was administered during surgery (or 
starting on day 2 in delayed treatment) and then daily 
for a total of 6 doses. Other studies focused on 
low-molecular-weight inhibitors to block signalling 
molecules downstream of TLRs receptors such as 
NLRP3 [40]. Similar effects have been observed by 
inhibiting the purinergic P2X7 receptor, which is 
activated by ATP released from dying cells [41]. 
Alpha-1 antitrypsin (AAT) a naturally occurring 
anti-inflammatory protein, has been used in an 
experimental AMI model in mice and significantly 
reduced myocardial injury [42]. These various 
strategies have consistently shown that targeting the 
inflammatory response following MI ameliorates 
heart function outcome. Taking a similar approach, 
we focused on circulating EV following ischemic heart 
injury, as they have been demonstrated to act as 
crucial mediators of inflammation [43]. In patients 
with ST-segment elevation MI (STEMI), the increased 
number of EV has been associated with augmented 
release of particles by platelets, red blood cells, 
endothelial cells, or leucocytes [44-47]. In line with 
previous studies in mice and humans [48, 49], our 
data confirms that the number of circulating EV 
increases during the acute phase of MI. Here we 
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added the findings that these circulating EV have 
direct cytotoxic effects on CM leading to the 
worsening of cardiac ischemic damage. In the present 
study, we assessed this hypothesis by different 
approaches: in vitro by adding EV post-MI into the 
medium of NRVM, ex vivo in isolated, perfused hearts 
and in vivo by inhibiting the release of EV during the 
very first phase of myocardial infarction. EV derived 
from plasma of animals that underwent coronary 
ligation were cytotoxic when added to the medium of 
NRVM, whereas those derived from plasma of 
healthy rats did not exert any toxic effects. 
Post-infarction circulating EV caused CM disruption 
when added to the perfusate of isolated heart as 
shown by the increased level of cTnI and LDH (both 
markers for the MI-diagnosis) and rapidly (within 40 
min) worsened heart functionality as assessed by the 
increase of end diastolic pressure. In vivo we used 
GW4869 as an inhibitor of EV generation and release, 
as it has been utilized to suppress the secretion of EV 
from LPS-induced sepsis model [21]. EV systemically 
released during the acute phase of infarct most likely 
originate from inflammatory cells since their cargo is 
enriched in IL-1α, IL-1β and Rantes. This was 
confirmed by the fact that a diminished amount of 
circulating EV subsequent to the GW4869 treatment 
was also accompanied by reduction of EV-associated 
pro-inflammatory cytokines and well-known, 
pro-inflammatory macrophage markers such as CD68 
and iNOS. Moreover, by reducing the number of 
circulating EV, the inflammatory response at site of 
injury was attenuated. The number of CD68+ 
infiltrating cells as well as the expression of TNF-α, 
were significantly reduced in the heart tissue of 
infarcted rats that received pre-treatment with the 
inhibitor GW4869 as compared to rats that were 
infarcted only. Consistently, we observed that 
intraperitoneal injection of GW4869, one hour before 
LAD ligation, effectively reduced the burst in 
circulating EV after MI. A single injection of GW4869 
was able to increase the number of surviving CM 
within 24 hrs, resulting in reduced fibrotic tissue in 
the long term after MI. Our approach was also 
validated in an ischemia/reperfusion model as the 
restoration of blood flow at the earliest possible time 
point remains the method of choice in all current 
treatment options of ischemia. We sought to evaluate 
whether reducing the number of circulating EV, 
during the acute phase of MI, has still effect on the top 
of the gold standard clinical practice. Indeed, our data 
confirmed this concept in I/R model, providing the 
basis for future investigations, and eventually to 
explore this approach in a large animal model. 
As such, we propose that the detrimental effect 
directly exploited by inflammatory EV on CM is also 
accompanied by EV-mediated autocrine signalling 
which amplifies the quantity of pro-inflammatory 
cytokines produced by the initial ischemic event and 
the recruitment of monocytes to the site of injury. This 
is in line with previous studies showing that EV from 
body fluids are internalized by the monocytic 
leukemia THP-1 cell line and activate the release of 
cytokines including IL-1β in a dose-dependent 
manner [50]. 
Plasma-derived EV promote NF-κB nuclear 
translocation in different cell types [50-52]. We 
demonstrated for the first time that this pathway is 
also activated in CM upon exposure to inflammatory 
EV. NF-κB activation is required for EV-mediated 
cytotoxicity, which is in line with evidence 
demonstrating that nuclear translocation of NF-κB 
induces apoptosis in CM [53]. We confirmed that 
EV-mediated triggering of NF-κB activation was 
strongly impaired by the functional blocking of TLR4 
as shown by Bretz et al [50]. Collectively, these data 
implicate that EV have signalling capacity; that they 
interact with TLR4 on the CM surface, and that this is 
determinant for signal initiation. As downstream 
effects of this pathway we showed activation of 
caspases 3 and 7 in combination with LDH release in 
healty CM, demonstrating that cell death mechan-
isms, ascrivable to apoptosis and/or pyroptosis, can 
contribute to heart function worsening in addition to 
necrotic events occurring during the acute phase of 
ischemia. Our data reveal that circulating EV post-MI 
play a double role in promoting and exacerbating 
inflammatory response and contributing to reduced 
heart function by directly inducing CM death. The 
latter was demonstrated on NRVM in vitro but most 
importantly it was also assessed ex vivo on adult CM. 
Considering that activated macrophages are a 
major source of pro-inflammatory cytokines and play 
a critical role in the pathogenesis of MI, we selected 
macrophages derived from bone marrow for the in 
vitro model to draw a comparison with the direct, 
in-vivo EV effects on CM. We are aware that resident 
heart macrophages and EV derived from those cells 
would have represented a relevant model to study, 
however it is known that after MI, monocytes 
recruitment occurs as early as 30 minutes after 
ischemia and that bone marrow and spleen acts as a 
reservoir from which monocytes are recruited [9, 54, 
55]. Heidt et al. suggested that following MI resident 
cardiac macrophages die and may be replaced by 
CCR2-expressing monocyte derived cells with potent 
pro-inflammatory properties [56]. Moreover the 
number of resident heart macrophages is very low in 
normal condition, thus making their isolation very 
challenging, even more difficult would be the in vitro 
culture of those cells and the subsequent enrichment 
Theranostics 2020, Vol. 10, Issue 6 
 
 
http://www.thno.org 
2783 
of EV into conditioned medium. On the other hand 
the direct isolation of EV from tissue, remain 
technically challenging [22]. In our experiments EV 
derived from bone marrow-derived M1 macrophages 
recapitulated the functional effects of those derived 
from the plasma of infarcted rats. Although it is 
generally accepted that activation in M1, but not M2, 
macrophages contributes to cardiac remodelling after 
MI [57], a direct causal relationship between the 
release of EV by M1 and their cytotoxic effect on 
NRVM has not been demonstrated previously. 
 
 
Figure 6. TLR4-NFkB axis regulates in vitro plasma-derived EV effects. (A) Quantification of plasma derived EV cytotoxicity on rat primary neonatal cardiomyocytes 
(NRVM) using the TLR4-specific inhibitor TAK242. Representative images of 5 independent experiments treated with 5 different pools of EV. Viable cells stain green, dead cells 
red. (B) Evaluation of NFkB nuclear translocation in NRVM. DAPI mask was used to detect NFkB nuclear fraction. Dots in graphs represent the number of different 
plasma-derived EV tested in each experimental condition. (C) WB analysis and quantification of nuclear translocation of NFkB (n=4 independent experiments). Quantification 
data are presented as nuclear/cytosol ratio within the same treatment and expressed as mean fluorescent intensity fold change versus w/o EV. All data are presented as mean ± 
SEM and analyzed by one-way ANOVAs with post-hoc Bonferroni multiple comparisons correction (*p < 0.05, **p < 0.01). Mean, SEM and statistics are reported in full in Table 
S6. 
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Figure 7. Bone marrow-derived macrophages and extracellular vesicles characterization. (A) Experimental design of bone marrow-derived macrophage 
purification and polarization protocol. (B) Relative expression of specific M1 and M2 genes. Data show 2-DDCt values vs. MF macrophages; n=6 independent experiments (M1 
markers); n=4 independent experiments (M2 marker). (C) Western blot analysis of specific macrophage markers. Quantitative densitometric data were normalized by GAPDH 
(n=5 independent experiments). (D) Representative dynamic light scatter profile of particle size and concentration of BMDM derived EV. Red lines represent standard deviations. 
(E) Western blot analysis of specific exosomal markers TSG101 and CD63. All data are presented as mean ± SEM and analyzed by one-way ANOVAs with post-hoc multiple 
comparisons using Bonferroni correction (*p < 0.05, **p < 0.01). Mean, SEM and statistics are reported in full in Table S7. 
 
Our in vitro and ex vivo functional tests were 
performed by comparing the same number of 
circulating particles derived from healthy or infarcted 
rats. Cytotoxic effects might be exacerbated following 
MI in vivo not only by the more noxious nature of the 
circulating inflammatory EV, but also by the 
significant increase in their number, thus opening a 
valid prospective approach for targeting detrimental 
aspects of the inflammatory process following 
ischemic injury. 
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Figure 8. TLR4-NFkB axis regulates in vitro macrophages-derived EV effects. (A) Evaluation of BMDM derived EV cytotoxicity on rat primary neonatal 
cardiomyocytes using the TLR4-specific inhibitor TAK242. Data refers to 6 independent experiments treated with 6 different pools of EV. Viable cells stain green, dead cells red. 
(B) Evaluation of NFkB nuclear translocation in NRVM using the TLR4-specific inhibitor TAK242. DAPI mask was used to detect NFkB nuclear fraction. Dots in graphs present 
the numbers of different BMDM-derived EV tested in each experimental condition. (C) WB analysis and quantification of nuclear translocation of NFkB using the TLR4-specific 
inhibitor TAK242 (n= 4 independent experiments). Quantification data are presented as nuclear/cytosol ratio within the same treatment and expressed as mean fold change in 
fluorescence intensity versus w/o EV. All data are presented as mean ± SEM and analyzed by one-way ANOVAs with post-hoc multiple comparisons using Bonferroni correction 
(*p < 0.05, **p < 0.01). Mean, SEM and statistics are reported in full in Table S8. 
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From a translational perspective, the approach 
used here is limited as the injection of inhibitor was 
performed before the coronary ligation. To date we do 
not know whether a single injection post-MI (at time 
of reperfusion) would provide benefits to a 
comparable degree. This aspect, as well as the 
possibility of using more specific approaches (i.e. 
silencing of proteins implicated in the active transport 
of intracellular vesicles) to specifically inhibit the 
release of EV from macrophages in a desirable time 
window, will be a focus of future studies. As 
presented in this study we cannot exclude that the 
beneficial effects of GW4869 on cardiac function is 
due to multiple effects such as the reduction of 
exosome release from cells other than macrophages 
(neutrophils, endothelial cells and platelets) as well as 
a direct effect on MΦ polarization, that has not been 
addressed here. The present study provides proof of 
concept for a new mechanism of EV-induced 
cytotoxicity, and offers a new perspective for the 
intervention and treatment of inflammation-related 
diseases, such as heart acute ischemia. 
Methods 
Animal experiments 
Experimental protocols were approved by the 
Local Veterinary Authority (TI-10-17, TI-08-18). All 
procedures conformed to the directive 2010/63/EU of 
the European Parliament. Two different models of 
myocardial ischemic injury (MI) were used: 
permanent coronary artery ligation (LAD) and acute 
ischemia/reperfusion (I/R). MI was induced in 
healthy Wistar male rats (250-300g body weight) 
anesthetized with a cocktail of Ketamine (ketasol100, 
100mg/Kg) and Xylazine (Rompun 2%, 8mg/Kg), 
intubated and ventilated. The left anterior descending 
artery was ligated with a 4.0 silk suture. In I/R 
operated animals, the coronary ligature was released 
after 30 min whereas the left coronary artery was not 
ligated in sham-operated group. The chest was then 
closed, pneumothorax was reduced and the rats were 
treated with Meloxicam (0,5mg/kg) for 5 days after 
surgery. Sixty minutes before coronary artery 
occlusion, animals were injected intraperitoneally (IP) 
with a chemical inhibitor of neutral sphingomyelinase 
(GW4869, Sigma 5mg/Kg) or diluent solution 
(Vehicle, DMSO 1:3v/v PBS1X). 24 hrs after injection, 
rats underwent tail vein blood sampling. Sedated rats 
were subjected to transthoracic echocardiography at 
24 hrs, 7 and 28 days post-MI using Vevo2100 
echocardiography system (VisualSonic System 2100) 
equipped with a 15MHz linear transducer. Under 
ECG monitoring of heart rate, 2D images of hearts 
were acquired in parasternal long axis and short axis 
(apex, mid and base levels) views. Left ventricle (LV) 
ejection fraction (LVEF), LV end-diastolic volume 
(LVDV) and LV end-systolic volume (LVSV) were 
measured by Simpson’s analysis. Hemodynamic 
analysis was performed at day 28 using a Millar 
pressure-volume conductance catheter. Rats were 
anesthetized with an IP injection of Ketamine 
(ketasol100, 100mg/Kg) and Xylazine (Rompun 2%, 
8mg/Kg). The trachea was cannulated and the animal 
connected to a rodent ventilator. The catheter was 
introduced through the right carotid artery into the 
ascending aorta and then into the LV cavity. After 
hemodynamic measurements, animals were 
sacrificed.  
Rat bone marrow-derived macrophages 
isolation, polarization and characterization 
The femur was isolated from euthanized Wistar 
male rats and marrow was flushed into a cold PBS 
solution containing 2% fetal bovine serum (FBS). 
Mechanically dissociated cells were incubated on ice 
with three volume of 0.8% NH4Cl solution to remove 
red blood cells. 106 cells/cm2 were seeded in tissue 
culture plates (Corning Constar) and cultured in 
Iscove's Modified Dulbecco's Medium (IMDM, Gibco) 
supplemented with 10% FBS, 1% v/v penicillin- 
streptomycin (Life Technologies) 10ng/ml M-CSF 
(RayBiotech). After 7 days, bone marrow-derived 
macrophages (MΦ) were polarized to inflammatory 
M1 with IMDM, 1% v/v penicillin-streptomycin, 
10ng/ml M-CSF supplemented with 100ng/ml TNFα 
(ApexBio) and 100ng/ml IFNγ (RayBiotech). The 
non-inflammatory BMDM-M2 profile was induced by 
supplementing the culture medium with 20ng/ml 
IL-4, 20ng/ml IL-10 and 20ng/ml IL13 (RayBiotech). 
Extracellular vesicles isolation and purification  
EV were isolated from citrate plasma samples or 
macrophages supernatant by differential centrifuga-
tion. Briefly, samples were centrifuged at 3000g (20 
min) followed by filtration through a 0.2μm 
membrane and centrifugation at 10000g (30 min) to 
remove cellular debris. EV were than pelleted by 
ultracentrifugation at 100000g (18h) using a Beckman 
Optima Max-TL ultracentrifuge (Beckman Coulter). 
BMDM-EV pellets were re-suspended in 100µL PBS, 
pH 7.4, and stored at -80°C. Plasma EV-enriched 
pellets underwent washing step (by diluition in 3ml 
PBS 1X ) and further centrifuged at 10000g (20 min) 
and 20000g (30 min) with a final step of 
ultracentrifuge at 100000g (18h). Plasma-EV pellets 
were then re-suspended in 100 µL PBS, pH 7.4, and 
stored at -80°C. EV numbers and size were measured 
using Nanosight Technology (Malvern Instruments). 
EV characterization was assessed by the presence of 
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TSG101 (Abcam #12501, 1:1000), and tetraspanin 
CD63 (Invitrogen #MA5-31276, 1:1000) CD81 
(Invitrogen #MA517937, 1:1000) and the absence of 
contaminants GRP94 (Abcam #108606, 1:500), 
Apolipoprotein A1 (Invitrogen #701239, 1:500), 
Albumin (Abcam, #ab207327, 1:2000). 
Extracellular vesicles cytokine content analysis  
EV content of multiple cytokines were simul-
taneously determined using enzyme-linked immuno-
sorbent assay (Multi-Analyte ELISArray for Rat, 
Qiagen) following manufacturer’s instructions. EV in 
sample dilution buffer were briefly sonicated and 1010 
EV/well were analysed. Sample dilution buffer 
without EV was analysed as experimental blank.  
Lipid extraction and exosomes LC-MS/MS 
ceramide content quantification 
Sphingolipid extraction and LC-MS/MS analysis 
were performed as already described elsewhere [58]. 
Briefly, sphingolipids from plasma-purified exosomes 
were extracted using a monophasic chloroform/ 
methanol/water mixture (30:60:10, v/v) and analysed 
by a LC Dionex 3000 UltiMate (Thermo Fisher 
Scientific,) coupled to a tandem mass spectrometer AB 
Sciex 3200 QTRAP (AB Sciex,). Separation was 
achieved by a reversed-phase BEH C-8 100 x2.1 mm 
x1.7 µm analytical column by a linear gradient 
between eluent A (water 0.2% formic acid 2mM 
ammonium formate) and eluent B (methanol 0.2% 
formic acid 2mM ammonium formate). Quantitative 
analysis was performed interpolating each peak area 
of analyte/area IS (ceramide C12:0, 200 pmol) with 
calibration curve of each sphingolipids.  
Langendorff ex vivo functional assays 
Hearts were excised from anesthetized rats; the 
aorta was immediately cannulated on the Langen-
dorff perfusion system and perfused with 15 ml/min 
fix-flow modified HEPES-Krebs solution (pH 7.3 at 
37°C). A latex balloon was inserted into the left 
ventricle, inflated (minimum of 10 mmHg), and 
connected to a pressure transducer (Bridge Amp/ 
Power Lab 8/35; AD instruments) to monitor cardiac 
performance. After heart rate stabilization, hearts 
were perfused for 2 hours at constant flow with 30 ml 
of oxygenated modified HEPES-Krebs solution 
supplemented with 5 x 1010 EV [29]. Heart rate and 
end-diastolic pressure were constantly monitored. 
Recirculating perfusate samples were collected at 
regular time points to measure cardiac Troponin I 
release (High Sensitivity Rat Cardiac Troponin-I 
ELISA, Life Diagnostics) and LDH release (cyQUANT 
LDH cytotoxicity assay kit, Invitrogen).  
Neonatal rat ventricular cardiomyocyte 
isolation and culture  
1-3 days old neonatal rats were used as organ 
donors for in vitro neonatal cardiomyocyte cell 
cultures (NRVM). Pups were decapitated using sterile 
scissors, and the chest was opened along the sternum 
to allow access to the chest cavity and the heart. 
Hearts were extracted from the body and transferred 
immediately into plates containing 1X ADS Buffer, on 
ice. After atria removal, hearts were processed for CM 
isolation as previously described [59]. 
Cytosolic and nuclear fractionation, total 
protein isolation and western blot analysis 
Cells were centrifuged at 6900 rpm and pellets 
were suspended in 100µl cytosolic lysis buffer (20mM 
Tris-HCl pH7,8, 50mM KCl, 0.1mM DTT, 1mM 
PMSF), supplemented with protease inhibitors 
(SIGMA FAST TM Protease Inhibitor Tablets, Sigma), 
and vortexed at maximum speed for 30sec. Cytosolic 
protein fractions were collected after centrifugation at 
14100rpm for 30 sec at 4°C. Nuclear pellets were 
suspended in 50µl nuclear lysis buffer (20mM 
Tris-HCl pH7,8, 50mM KCl, 0.1mM DTT, 1mM PMSF, 
1% NP40) supplemented with protease inhibitors 
(SIGMAFASTTM Protease Inhibitor Tablets, Sigma), 
and vortexed at maximum speed for 15min. Nuclear 
samples were then pulse sonicated for 10sec and 
supernatants were collected after centrifugation at 
14100 rpm for 20min at 4°C. 
Total proteins were extracted by lysing 
exosomes or cells with ice-cold RIPA buffer (25mM 
Tris pH:7,4 , 150mM NaCl, 1mM EDTA, 1% Igepal 
CA630, 1% Na-deoxycholate, 1.01% sodim dodecyl 
sulfate; SDS) supplemented with protease inhibitors 
(SIGMAFASTTM Protease Inhibitor Tablets, Sigma) for 
30 min at 4°C under agitation. EV and cell lysates 
were centrifuged at 9600 rpm for 15min at 4°C and 
protein concentrations were determined using BCA 
kit (Sigma). Equal amount of total proteins were 
boiled with Laemmli SDS sample buffer 6X (0.375M 
Tris-HCl pH 6.8, 12% SDS, 60% glycerol, 0.6 M DTT, 
20%(v/v) β-mercaptoethanol, 0.2% (w/v) bromo-
phenol blue; VWR International), separated on 4–20% 
Mini-PROTEAN®TGX™ Precast Gel (Bio-Rad), and 
transferred onto PVDF membranes with a semi-dry 
transfer system (Bio-Rad). The membranes were first 
blocked for 1 hr in Odyssey Blocking Buffer (LI-COR 
Biosciences) diluted 1:1 in distilled water and 
supplemented with 0.2% Tween 20 (OBB-T), then 
incubated with the appropriate primary Ab diluted in 
OBB-T at 4°C overnight under gentle agitation. The 
membranes were then incubated with an IRDye® 
680RD or 800CW goat anti-mouse or goat anti-rabbit 
secondary Ab (LI-COR Biosciences; 1:15000 dilution 
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in OBB-T) at RT for 2 h. The infrared signal was 
detected using the Odyssey CLx Detection System 
(LI-COR Biosciences). M0 polarization was assessed 
with the following primary antibodies: iNOS (abcam 
#3523, 1:500), TLR4 (Santa Cruz #sc293072, 1:500), 
CD68 (abcam #31630, 1:100) and normalized for 
GAPDH (abcam #181602, 1:1000) protein level. 
NRVM nuclear and cytosolic fractions were probed 
with p-NF-kBp65 ab (abcam #86299, 1:1000) and 
normalized respectively for H3 Histone (abcam 
#176842, 1:1000) and GAPDH (Abcam #ab181602). 
In-vitro neonatal rat ventricular myocyte 
viability assay 
To assess cytotoxic effects of EV, NRVM cells 
were cultured for 5 hours in serum-free medium. 
After starvation, NRVM were pre-treated with a TLR4 
inhibitor (0.1µM TAK242, InvivoGen) for 90 min and 
EV were then added at 107/cm2 concentration as 
determined by Nanosight. Number of particles to be 
used in vitro experiments were determined previously 
in a dose response experiments [60]. 12h later, cells 
were stained with CellstainTM Double Stain kit 
(dojindo) for 30 min at 37°C. 4X images were acquired 
with fluorescence microscopy (Nikon Eclipse-Ti) and 
the number of PI positive cells were quantified using 
ImageJ software (NIH). 
Statistical analysis 
IBM SPSS statistics 24 (IBM Corp, Armonk, NY) 
and GraphPad Prism V7.0 (Graphpad Software, San 
Diego, CA) were used for statistical analyses. The 
distribution of each variable was assessed by the 
Kolmogorov-Smirnov test. Variables were expressed 
as mean ± SEM (standard error of measurement) and 
analyzed by Student’s T test or One-way ANOVA test 
with post-hoc Bonferroni tests for multiple 
comparisons. Two-way ANOVA tests with post-hoc 
Bonferroni tests for multiple comparisons were used 
to analyze echocardiographic recordings and data 
from ex vivo Langendorff experiments. Survival 
probability of in vivo experiments was assessed with 
Kaplan-Meier curves. P-values of less than 0.05 were 
considered significant. 
Additional methods are provided in the online 
supplementary methods.  
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